Currently Viewing:
Currently Reading
Top 5 Diabetes Stories for the Year
November 27, 2015
Top Hepatitis C Articles for the Year
November 26, 2015 – AJMC Staff
Telehealth Advancing, but Obstacles Remain
November 26, 2015 – Jackie Syrop
Mississippi to Pay for Bariatric Surgery to Combat Obesity
November 25, 2015 – Mary K. Caffrey
5 Things About Wellness and Screening
November 25, 2015 – Laura Joszt
What We're Reading: Coke Interfered With Work of Anti-Obesity Group
November 25, 2015 – AJMC Staff
What We're Reading: Hospitals Can Save More Money With Private Rooms
November 25, 2015 – AJMC Staff
Americans' Satisfaction With Healthcare Quality, Cost, and Coverage No Better Than Before the ACA
November 24, 2015 – Laura Joszt
What We're Reading: Pharma-Payer Alliance on Drug Pricing
November 24, 2015 – AJMC Staff

Top 5 Diabetes Stories for the Year

Diabetes is a growing epidemic in the United States and new research has indicated that half of healthy 45-year-olds will develop pre-diabetes and one-third will develop diabetes at some point.
Diabetes is a growing epidemic that is quickly spiraling out of control in the United States. New research has indicated that half of healthy 45-year-olds will develop pre-diabetes and one-third will develop diabetes at some point.
The disease affects approximately 30 million Americans and is the seventh leading cause of death in the United States, according to data from the National Diabetes Statistics Report, 2014.
Here are the top 5 articles from the last year on diabetes.
Toujeo and Afrezza: New and Improved Insulins, Limited by FDA Labeling Constraints
Two new insulins marketed by Sanofi offer improved options for patients: Toujeo is longer acting than its predecessor, Lantus. Afrezza, an inhaled insulin, is gaining praise from patients, if not from Wall Street.

Trial data indicate that Toujeo controls glycated hemoglobin (A1C) levels about as well as Lantus, an insulin glargine formulation approved in the year 2000 that has just lost patent protection after years of blockbuster sales. Toujeo lasts longer than Lantus, however.1 It also provides the body a steadier stream of insulin1 and is associated with a significantly lower risk of nocturnal hypoglycemia.

Afrezza performed similarly in a phase 3 trial. It roughly matched an existing competitor, insulin aspart (Novolog), in A1C reduction, and slightly outperformed it in several secondary ways. Afrezza use was associated with less hypoglycemia, lower fasting blood glucose, and slight weight loss rather than slight weight gain. It also reached peak levels very quickly, in just 12 to 14 minutes on average.
Read the article.

Sanofi Addresses Need for Spirometry Before Physicians Can Prescribe Afrezza
Rarely does a new therapy generate as much divided opinion and passion as Afrezza, the inhaled insulin developed by MannKind Corporation and now marketed by Sanofi.

The fast-acting human insulin, administered through an inhaler that fits in a palm, has won loyal fans among users with type 1 diabetes mellitus (T1DM). Those who praise the product cite its ability to provide better glycemic control as well as a winning design, which offers convenience that those with T1DM have long sought.

And then, there are the skeptics: throughout the spring, analysts who follow MannKind reported slower than expected sales and reluctance from some physicians to prescribe the product, often because of a requirement imposed by the FDA at approval: Because the insulin powder is inhaled, underlying lung problems must be ruled out before a patient can gain access to the therapy. (Afrezza is not indicated for patients with chronic obstructive pulmonary disorder or other chronic lung diseases, such as asthma. Safety and efficacy in patients who smoke have not been established.)

Ruling out lung problems requires spirometry, a test that until now may have been uncommon among endocrinologists, although it better known among primary care physicians.
Read the article.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up